Versor Investments LP Grows Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Versor Investments LP grew its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLLFree Report) by 14.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,579 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,316 shares during the period. Versor Investments LP’s holdings in Collegium Pharmaceutical were worth $326,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Pacer Advisors Inc. increased its stake in shares of Collegium Pharmaceutical by 68.4% during the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after buying an additional 883,380 shares during the period. SummerHaven Investment Management LLC increased its stake in shares of Collegium Pharmaceutical by 1.1% during the fourth quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock valued at $1,048,000 after buying an additional 368 shares during the period. Natixis Advisors L.P. increased its stake in shares of Collegium Pharmaceutical by 152.9% during the third quarter. Natixis Advisors L.P. now owns 54,359 shares of the specialty pharmaceutical company’s stock valued at $1,215,000 after buying an additional 32,865 shares during the period. Loomis Sayles & Co. L P increased its stake in shares of Collegium Pharmaceutical by 32.7% during the third quarter. Loomis Sayles & Co. L P now owns 273,628 shares of the specialty pharmaceutical company’s stock valued at $6,116,000 after buying an additional 67,439 shares during the period. Finally, New York State Common Retirement Fund increased its stake in shares of Collegium Pharmaceutical by 1,475.5% during the fourth quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock valued at $6,190,000 after buying an additional 188,347 shares during the period.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $33.29 on Wednesday. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21. The company has a market cap of $1.09 billion, a PE ratio of 13.87 and a beta of 1.06. The business has a 50-day simple moving average of $37.36 and a two-hundred day simple moving average of $32.59. Collegium Pharmaceutical, Inc. has a fifty-two week low of $20.83 and a fifty-two week high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLLGet Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.25. The business had revenue of $149.75 million during the quarter, compared to the consensus estimate of $147.66 million. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. As a group, equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current fiscal year.

Analyst Ratings Changes

COLL has been the topic of several research reports. Truist Financial raised their price target on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, February 26th. Needham & Company LLC downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Piper Sandler downgraded Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price objective on the stock. in a research report on Friday, May 10th. Finally, StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Collegium Pharmaceutical has an average rating of “Hold” and an average target price of $39.00.

View Our Latest Stock Report on Collegium Pharmaceutical

Collegium Pharmaceutical Profile

(Free Report)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Read More

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLLFree Report).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.